“In other words, a very high number of women are being unnecessarily treated,” explains CNIO researcher Eva González-Suárez. “But at the moment there’s no way to avoid it”.

Her new study, published in Nature Communications, identifies a marker that discriminates precancerous breast lesions that will develop into tumours

The study also reveals that breast cancers originate in certain cells that the authors refer to as ‘infidel’

Researchers at Linköping University show how two important cancer-related proteins can be prevented from collaborating with each other. The discovery shows the way towards future medications to combat e.g. neuroblastoma in children. Their study has been published in the journal Nature Communications.

This work, published in Nature Communications, opens new avenues for identifying tumors with a high risk of developing metastases and may improve the classification of breast cancer patients.

Researchers at the Josep Carreras Leukaemia Research Institute (IJC) discover that a single molecular switch, HDAC7, controls both the development of healthy immune cells and the aggressiveness of diffuse large B cell lymphoma — with major implications for patient prognosis.

Kyoto, Japan -- While modern life includes many conveniences, humans are still incessantly exposed to a variety of metabolic stresses we have never experienced before. Our immune systems are constantly trying to protect us, and CD8⁺ T cells in particular -- also known as killer T cells -- play an essential role in attacking tumors.

A team of researchers from Kyoto University's Center for Cancer Immunotherapy and Immunobiology, CCII, and the RIKEN Center for Integrative Medical Sciences was motivated to investigate how metabolic stress can persist in the immune system and its consequences, particularly on anti-tumor immunity.

"Since each one of us experiences variable types of stress throughout our lives, we were interested in finding where and how that stress may influence our health," says first author Masaki Tajima of CCII.

A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found a tolerable dosing schedule with promising activity, according to results reported by Dana-Farber Cancer Institute medical oncologist Dr. Elizabeth Lee at the AACR Annual Meeting 2026, held April 17-22, in San Diego, Calif.